Skip to content

Low Disability Accumulation After 4-Year Ocrelizumab Therapy in Treatment-Naive Patients With Early-Stage Relapsing-Remitting Multiple Sclerosis: Data From the Phase IIIb ENSEMBLE Study

As MS is a progressive disease from the onset, initial and sustained treatment with high-efficacy therapies is important to maintain patient function. Here, we report the 4-year disability progression and efficacy data from patients with relapsing-remitting MS who received first-line OCR therapy.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically